Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease
Nutrients · 24.10.2023 · 15 (21) · 4507
DOI: 10.3390/nu15214507 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Nutrients, online erschienen am 24.10.2023. Verfasst von Pilar Navarro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, 13700 Ciudad Real, Spain. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Inflammatory Bowel Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Non-alcoholic fatty liver disease (NAFLD) is a common concomitant condition in patients with inflammatory bowel disease (IBD). We aim to assess the magnitude of this association.
Methods
We searched MEDLINE, EMBASE and Scopus libraries for the period up to February 2023 to identify studies reporting cohorts of IBD patients in which NALFLD was evaluated.
Results
Eighty-nine studies were analyzed. The overall prevalence of NAFLD was 24.4% (95%CI, 19.3–29.8) in IBD, 20.2% (18.3–22.3) in Crohn’s disease and 18.5% (16.4–20.8) for ulcerative colitis. Higher prevalence was found in male compared to female patients, in full papers compared to abstracts, and in cross-sectional studies compared to prospective and retrospective ones. The prevalence of NAFLD in IBD has increased in studies published from 2015 onwards: 23.2% (21.5–24.9) vs. 17.8% (13.2–22.9). Diagnostic methods for NAFLD determined prevalence figures, being highest in patients assessed by controlled attenuation parameter (38.8%; 33.1–44.7) compared to ultrasonography (28.5%; 23.1–34.2) or other methods. The overall prevalence of fibrosis was 16.7% (12.2–21.7) but varied greatly according to the measurement method.
Conclusion
One-quarter of patients with IBD might present with NAFLD worldwide. This proportion was higher in recent studies and in those that used current diagnostic methods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, 13700 Ciudad Real, Spain.
- Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), 45004 Toledo, Spain.
- Fundación del Hospital Nacional de Parapléjicos para la Investigación y la Integración. 45007 Toledo, Spain.
- Research Unit Complejo Hospitalario La Mancha Centro, 13600 Alcázar de San Juan, Spain.
- Instituto de Investigación Sanitaria Princesa, 28006 Madrid, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), 28006 Madrid, Spain.
ORCID-Profile: Lucía Gutiérrez-Ramírez, Antonio Tejera-Muñoz, Ángel Arias, Alfredo J Lucendo
Zitieren
APA
Navarro, P., Gutiérrez-Ramírez, L., Tejera-Muñoz, A., Arias, Á., & Lucendo, A. J. (2023). Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease. Nutrients, 15(21), 4507. https://doi.org/10.3390/nu15214507
Vancouver
Navarro P, Gutiérrez-Ramírez L, Tejera-Muñoz A, Arias Á, Lucendo AJ. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease. Nutrients. 2023;15(21):4507. doi:10.3390/nu15214507
BibTeX
@article{Navarro2023,
author = {Navarro, Pilar and Gutiérrez-Ramírez, Lucía and Tejera-Muñoz, Antonio and Arias, Ángel and Lucendo, Alfredo J},
title = {Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {21},
pages = {4507},
doi = {10.3390/nu15214507}
}
EUVIMED